36 results about "Feline immunodeficiency virus" patented technology

Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and / or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.

Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV vaccine followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID50) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID50) given eight months after the initial challenge without any intervening booster.

Feline immunodeficiency virus antigens from gp160 envelope protein, gp120 envelope protein and p24 gag protein, useful for the diagnosis, treatment, and prevention of FIV. The invention may also be used to purify FIV.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The

The present invention discloses a method for treating patients having the FIV associated symptoms or patients carrying or infected by the FIV or having antibodies against the FIV is disclosed using Product R, a peptide-nucleic acid preparation.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified and neurotropically active modified venom composition containing alpha-neurotoxins that target a nicotinic acetylcholine receptor.

The invention provides a cocktail vaccine that is anti-immune tolerance and anti-immunodeficiency virus and its application. Said cocktail vaccine at least comprises two or more elements and any viral antigen recombinant protein and medical shaping. Said element is recombinant DNA and / or recombinant virus; it is chosen from (A) neutralizing antibody, receptor antagonist, membrane fusion blocking agent, cell factor coding sequence, and / or DNA interference sequence; (B) immunoadjuvants coded sequence; (C) antigen gene, viral antigen and immunoadjuvants fusion gene, viral antigen epitope coded sequence, multi-epitope fusion gene and / or viral antigen epitope -MHC-I SCT gene; (D) two seven-peptide multiplexed sequence HR1 and HR2 of membrana capsularis virus fusion protein and / or coded sequence of its polymer HR212. The expression carrier of all antiviral elements comprises recombinant DNA carrier, vaccinia virus carrier and / or adenoviral carrier.

The present disclosure provides methods and compositions for reducing the reservoir of latent immunodeficiency virus in an individual, and for treating an immunodeficiency virus infection in an individual.

The invention discloses a preparation method of an SIV (simian immunodeficiency virus) vector. A culture dish is treated with collagen by a calcium phosphate coprecipitation transfection process; and in the transfection process, an Opti-MEM culture medium is used, and the DNA (deoxyribonucleic acid) concentration is increased. The invention has the advantages of ingenious concept and low production cost; and the prepared tolvaptan tablet has the advantages of high in-vitro dissolution, high drug bioavailability and favorable clinical curative effect.

The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention further provides methods of making a subject cell. The invention further provides screening methods for identifying agents that activate a latent immunodeficiency virus; and screening method for identifying agents that block reactivation of latent immunodeficiency virus expression in response to T cell activation signals. The invention further provides agents identified in the subject screening assays. The invention further provides methods of treating an immunodeficiency virus infection.

The present invention relates tocompounds and compositions for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of said derivatives for the manufacture of a medicament for the treatment or prevention of feline leukemia virus (FeLV) infections occurring alone or together with feline immunodeficiency virus (FIV) infections in cats.

The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated FIV or the determination of the potency of an inactivated FIV vaccine.

Method, device and kit for the detection of antibodies directed to Feline Immunodeficiency Virus (FIV). The method includes contacting the felid biological sample with FIV env polypeptide and detecting whether the polypeptide substantially binds to the antibody in the biological sample. The method will detect FIV antibodies in a sample from animals that have been naturally infected but the method will not detect antibodies in a sample from animals that have not been infected and that have not been vaccinated with an FIV vaccine after within about the previous five to eight weeks.

The invention relates to a nucleic acid combination product, a detection kit and a micro-fluidic chip. The nucleic acid combination product comprises at least two of the following detection primer pairs: a feline parvovirus primer pair, a feline coronavirus primer pair, a feline herpesvirus type I primer pair, a feline calicivirus primer pair, a feline leukemia virus primer pair, a feline immunodeficiency virus primer pair, a feline astrovirus primer pair, a feline rotavirus primer pair, a cat vaccinia virus primer pair and a cat reovirus primer pair. The nucleic acid combination product can be used for detecting at least two feline pathogenic viruses in the sample to be detected at one time, and is good in specificity and relatively high in detection sensitivity.

The invention discloses a recombinant plasmid. The recombinant plasmid contains a gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses recombinant mycobacterium smegmatis which can stably express the gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses an AIDS vaccine and a preparation method thereof. The AIDS vaccine contains the recombinant mycobacterium smegmatis, is easy to culture, grows fast and saves time, labor, material resources and financial resources. The vaccine comprising three strains of the recombinant mycobacterium smegmatis ZWY2 exhibiting the SIV gp120 antigen proteinon the surface can stably exhibit the SIV gp120 antigen protein on the surface of the mycobacterium smegmatis ZWY2 and has the immunological effect in C57 mice far superior to that of intracellular expression of the antigen protein gp120 and that of the already published AIDS vaccine exhibiting gp120 on the surface based on adenovirus vector construction.

The invention relates to the technical field of molecular biomedicine, in particular to a PCR (Polymerase Chain Reaction) detection kit for cat and / or dog pathogens, a detection method and application. The kit is used for detecting canine distemper virus, canine influenza A virus, canine parainfluenza virus, canine parvovirus, canine coronavirus, canine rotavirus, canine babesia, canine ascaris, canine Ehrlichia, canine brucella, rabies virus, borrelia burgdorferi, reference gene ACTB, feline herpes virus, feline calicivirus and feline parvovirus. The kit comprises primers and probes of feline coronavirus, feline immunodeficiency virus, feline leukemia virus, feline mycoplasma, feline mycoplasma, feline chlamydia, giardia, toxoplasma, bartonella and reference gene GAPDH, collected DNA and RNA are added into the kit, a real-time fluorescence PCR instrument is adopted for PCR reaction, FAM, HEX, ROX and CY5 fluorescence signals are collected in each cycle, analysis of related pathogens is carried out, and the kit can be used for detecting the feline and the canine. Compared with a traditional detection method, the method has the advantages of higher specificity and higher sensitivity.

The invention relates to the technical field of biology, and particularly discloses a recombinant immunodeficiency plasmid and virus and application thereof. The immunodeficiency plasmid comprises LTR, gag gene, nucleotide sequence disclosed as SEQ ID No.1, vif gene, vpr gene, vpx gene, tat gene, rev gene, env gene and nef gene. The nucleotide sequence disclosed as SEQ ID NO.1 is introduced to the pathogenic SIVmac239 full-length plasmid frame to construct the immunodeficiency plasmid comprising a plurality of drug target spots, and packaging is performed in the 293T cell to generate immunodeficiency virus. The virus has the capacity for infecting target cells and the capacity of efficient replication, and is applicable to researching human immunodeficiency virus (HIV) in-vivo infection process, pathogeny characteristic, pathogenesis and immunoreaction and screening anti-HIV drugs and anti-HIV drug application strategies.

Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides method of using mycobacterium w for the management of HIV. According to present invention mycobacterium w when given intradermally is effective in prophylaxis and treatment of AIDS or AIDS related complex (ARC). It is found to improve immunity as well as CD4 count. It is found to eliminate symptoms like fever, diarrhea. The effect is seen even when no antiretrovirals are used.

A chimeric type 5 / type 11 or type 35 adenovirus vector, wherein a gene encoding the envelope protein of human immunodeficiency virus or its mutant having an equivalent function is integrated into a nonproliferation type 5 adenovirus in such a manner as allowing the expression and a gene encoding the fiber protein of the type 5 adenovirus is substituted by a gene encoding the fiber protein of a type 11 or type 35 adenovirus or a mutant having an equivalent function, has a lessened toxicity on the liver and can induce an extremely potent HIV-specific immune response. Thus, it is highly efficacious as a drug for preventing HIV-infection.

The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The invention mainly relates to immuno comb array test paper for detecting an antibody of an SIV (simian immunodeficiency virus) as well as a preparation method and an application. A recombinant plasmid pGEX-4T-SIV for establishment of an immuno comb array is shown in the sequence table Seq No.3. An upper primer SIVF in a primer pair for establishment of the recombinant plasmid is shown in the sequence table Seq No.1, and a lower primer SIVR of the primer pair is shown in the sequence table Seq No.2. The establishment method comprises the following steps: the SOE (splicing overlapping extension)-PCR (polymerase chain reaction) primer pair is designed according to the nucleotide sequence of the SIV, SIV genes are amplified through SOE-PCR, and the recombinant plasmid pGEX-4T-SIV is established; finally, the immuno comb array for quickly detecting the antibody in blood or serum of an experimental monkey is prepared with a film chromatographic technique according to the enzyme linked immunosorbent assay principle and has good stability, specificity, sensitivity and repeatability.

The invention provides a cocktail vaccine that is anti-immune tolerance and anti-immunodeficiency virus and its application. Said cocktail vaccine at least comprises two or more elements and any viral antigen recombinant protein and medical shaping. Said element is recombinant DNA and / or recombinant virus; it is chosen from (A) neutralizing antibody, receptor antagonist, membrane fusion blocking agent, cell factor coding sequence, and / or DNA interference sequence; (B) immunoadjuvants coded sequence; (C) antigen gene, viral antigen and immunoadjuvants fusion gene, viral antigen epitope coded sequence, multi-epitope fusion gene and / or viral antigen epitope -MHC-I SCT gene; (D) two seven-peptide multiplexed sequence HR1 and HR2 of membrana capsular is virus fusion protein and / or coded sequence of its polymer HR212. The expression carrier of all antiviral elements comprises recombinant DNA carrier, vaccinia virus carrier and / or adenoviral carrier.

The invention provides vaccination protocols for administering immunogens to a primate host in order to promote the formation of neutralizing antibodies (NAbs) against primate immunodeficiency viruses. In some embodiments, the vaccination protocols comprise the step of administering to a primate host a first immunogen comprising at least one primate immunodeficiency virus Envelope (env) sequence having a first set of consensus glycosylation sequences, followed by a second immunogen comprising at least one primate immunodeficiency virus env sequence having a second set of consensus glycosylation sequences, wherein the differences between the first set of consensus glycosylation sequences and the second set of consensus glycosylation sequences comprise differences in consensus glycosylation sequences observed in HIV isolates obtained at different time points of a natural infection.

This invention is directed to a synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence within a packaging sequence of an RNA virus. Preferably, the viral packaging sequence is a retrovirus packaging sequence or the HIV-1 Psi packaging sequence. The RNA virus may be HIV-1, Feline Leukemia Virus, Feline Immunodeficiency Virus or one of the viruses listed in Table I. The conserved catalytic region may be derived from a hammerhead ribozyme, a hairpin ribozyme, a hepatitis delta ribozyme, an RNAase P ribozyme, a group I intron, a group II intron. The invention is also directed to multiple ribozymes, combinations of ribozymes, with or without antisense, and combinations of ribozymes, with antisense, and TAR decoys, polyTARs and RRE decoys targeted against the RNA virus. Vectors are also described. Further, methods of treatment and methods of use both in vivo and ex vivo are described.

A Bovine Immunodeficiency Virus BIV infected cell system and use are disclosed. The process is carried out by expressing reinforced EGFP under BIV infectious specific condition, constructing respondent Bovine Immunodeficiency Virus BIV infected reporting plasmid with nucleotide acid sequence in sequence table, transfecting it to BHK-21 cell, screening expressed cell system, mono-cloning and selecting high-expression EGFP negative cloning. It can be used to indicate BIV infection and activate BIV trans factor.

The present invention relates to compounds and compositions for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of said derivatives for the manufacture of a medicament for the treatment or prevention of feline leukemia virus (FeLV) infections occurring alone or together with feline immunodeficiency virus (FIV) infections in cats.